Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Francesca Palandri(Istituto Oncologico Romagnolo), Elisabetta Abruzzese(St. Eugenio Hospital), Alessandra Iurlo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Monica Crugnola(Ospedale di Parma), Alessia Tieghi(Azienda Sanitaria Unità Locale di Reggio Emilia), Roberto M. Lemoli(University of Genoa), Daniela Cilloni(Centre de Recherche Jean Pierre Aubert), Mario Tiribelli(University of Udine), Giulia Benevolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mirko Farina(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Eloise Beggiato, Alessia Moioli(University of Verona), Emilia Scalzulli(Policlinico Umberto I), Santino Caserta(University of Messina), Giuseppe A. Palumbo(University of Catania), Alessandro Isidori, Massimiliano Bonifacio(University of Verona), Giovanni Caocci, Gianni Binotto(University of Padua), Erika Morsia(Marche Polytechnic University), Andrea Duminuco(University of Catania), Novella Pugliese(Federico II University Hospital), Massimo Breccia(San Antonio College), Filippo Branzanti(University of Bologna), Elena Maria Elli(Azienda Ospedaliera San Gerardo), Florian H. Heidel(Universitätsmedizin Greifswald), Francesco Cavazzini(University of Ferrara), Alessandra Dedola(University of Bologna), Fabrizio Pane(Federico II University Hospital), Fabrizio Cavalca(Azienda Ospedaliera San Gerardo), Bruno Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Monica Bocchia(University of Siena)
Cited by 4
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464